StockData

CytoMed Therapeutics vs Quantum Cyber

GDTC and QUCY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GDTC and QUCY compare

CytoMed Therapeutics grew revenue faster over the last twelve months (367% versus −39.9% for Quantum Cyber).

CytoMed Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1227% compared with −3018% at Quantum Cyber.

CytoMed Therapeutics scores higher on the StockData Score (4 against 3 for Quantum Cyber), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGDTCQUCY
Size and price
Share price$0.774$0.630
Change, 1 year−59.7%−53.7%
Change, 5 years–−93.6%
Beta (5Y)−0.40–
Employees53
StockData Score
Total score4 (better)3
Valuation score00
Growth score11
Performance score11
Health score2 (better)1
Dividend score00
Growth
Revenue growth (TTM)367% (better)−39.9%
Revenue growth, 5Y average–1.7%
Profitability
Gross margin–72.6%
Operating margin–−3005%
Net margin−1227% (better)−3018%
FCF margin−1336% (better)−2045%
Return on equity−51.3% (better)−141%
Return on invested capital–−324%
Financial health
Debt / equity0.06–
Interest coverage–−43.2×
Current ratio5.175.56 (better)
Piotroski F-score12 (better)
Ownership
Held by institutions0.10%2.4%
Held by insiders25.9%–
Insider net buying, 12 months$729K (better)$0

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.